BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15771634)

  • 1. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study.
    Rattanachaiyanont M; Angsuwathana S; Techatrisak K; Tanmahasamut P; Indhavivadhana S; Leerasiri P
    J Obstet Gynaecol Res; 2005 Apr; 31(2):98-106. PubMed ID: 15771634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
    Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Wheeler DT; Bristow RE; Kurman RJ
    Am J Surg Pathol; 2007 Jul; 31(7):988-98. PubMed ID: 17592264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
    Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
    Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
    Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
    Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endometrial squamous metaplasia. An unusual response to progestin therapy of hyperplasia.
    Miranda MC; Mazur MT
    Arch Pathol Lab Med; 1995 May; 119(5):458-60. PubMed ID: 7748076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.
    Vereide AB; Kaino T; Sager G; Ørbo A;
    Gynecol Oncol; 2005 Jun; 97(3):740-50. PubMed ID: 15885761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia.
    Amezcua CA; Zheng W; Muderspach LI; Felix JC
    Gynecol Oncol; 1999 Apr; 73(1):126-36. PubMed ID: 10094893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.
    Penner KR; Dorigo O; Aoyama C; Ostrzega N; Balzer BL; Rao J; Walsh CS; Cass I; Holschneider CH
    Gynecol Oncol; 2012 Mar; 124(3):542-8. PubMed ID: 22079678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.
    Pérez-Medina T; Bajo J; Folgueira G; Haya J; Ortega P
    Gynecol Oncol; 1999 May; 73(2):299-304. PubMed ID: 10329050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of metastatic endometrial endometrioid adenocarcinoma while on progestin therapy for endometrial hyperplasia.
    Rubatt JM; Slomovitz BM; Burke TW; Broaddus RR
    Gynecol Oncol; 2005 Nov; 99(2):472-6. PubMed ID: 16099019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
    Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
    Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathological analysis in cases with glandular and atypical glandular hyperplasia treated with gestagens].
    Ivanov S
    Akush Ginekol (Sofiia); 2005; 44(4):18-20. PubMed ID: 16028373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
    Ørbo A; Arnes M; Hancke C; Vereide AB; Pettersen I; Larsen K
    Gynecol Oncol; 2008 Oct; 111(1):68-73. PubMed ID: 18684496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
    Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
    Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
    Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
    J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives.
    Shen ZQ; Zhu HT; Lin JF
    Obstet Gynecol; 2008 Aug; 112(2 Pt 2):465-7. PubMed ID: 18669766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.